ASX - Delayed Quote AUD

Neuren Pharmaceuticals Limited (NEU.AX)

Compare
13.13 +0.02 (+0.15%)
At close: October 18 at 4:10 PM GMT+11

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director 1.07M -- --
Ms. Lauren Frazer C.A. CFO & Company Secretary -- -- --
Mr. Lawrence Glass BA (Biology) Chief Science Officer -- -- --
Mr. Gerry Zhao Vice President of Corporate Development -- -- --
Dr. Liza A. Squires M.D. Chief Medical Officer -- -- --

Neuren Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 9092 0480 https://www.neurenpharma.com
Sector:?
Healthcare
Industry:?
Biotechnology

Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Corporate Governance

Neuren Pharmaceuticals Limited’s ISS Governance QualityScore as of October 1, 2024 is 5. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 1; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 26, 2024 at 11:17 PM UTC

Neuren Pharmaceuticals Limited Earnings Date

Recent Events

Related Tickers